Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E2902||ECOG||A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients over Age 60 in First Remission||Adult CIRB - Late Phase Emphasis||Completed|
|9653||ETCTN||Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder||Adult CIRB - Early Phase Emphasis||Completed|
|AHOD0431||COG||A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease||Pediatric CIRB||Completed|
|NRG-GI001||NRG||Randomized Phase III Study of Focal Radiation Therapy for Unresectable; Localized Intrahepatic Cholangiocarcinoma||Adult CIRB - Late Phase Emphasis||Completed|
|10130||ETCTN||A phase I study of single agent tazemetostat in subjects with advanced solid tumors and B-cell lymphomas with hepatic dysfunction||Adult CIRB - Early Phase Emphasis||Completed|
|S0232||SWOG||Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant||Adult CIRB - Late Phase Emphasis||Completed|
|ARST08P1||COG||A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12; Anti-IGF-IR Monoclonal Antibody; IND #100947; NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Pilot Study||Pediatric CIRB||Completed|
|SWOG-9007||SWOG||Cytogenetic Studies in Leukemia Patients||Adult CIRB - Late Phase Emphasis||Completed|
|ACCL0934||COG||A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Groupwide Phase III Study||Pediatric CIRB||Completed|
|GOG-0250||GOG||A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297||Adult CIRB - Late Phase Emphasis||Completed|